Skip to main content

GLP-1 Meds Can Work Wonders for Kidney Health

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 11, 2025.

By Ernie Mundell HealthDay Reporter

TUESDAY, Feb. 11, 2025 -- Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new research shows.

Compared to another common class of kidney medications, called DPP4is, GLP1-RA medications did better in helping slow the progression of kidney disease, keeping kidney disease patients out of the hospital and helping them survive.

“The benefits of GLP1-RA therapy for blood glucose management are well known, but our research provides much-needed evidence in support of the [kidney]-protective effect of GLP1-RAs in high-risk patients with moderate to advanced chronic kidney disease,” said study first author Dr. Shuyao Zhang. She is an assistant professor of internal medicine at UT Southwestern in Dallas.

Over the two-year study, Zhang's team followed the medical records of 64,705 veterans with diabetes and chronic kidney disease (CKD), half of whom took a DPP4i medication and half of whom took a GLP1-RA.

Folks who took one of the latter class of drugs were 16% less likely to die, 10% less likely to need hospital care and 36% less apt to see their kidney disease progress, compared to patients taking a DPP4i drug, the study found.

“People with diabetes and chronic kidney disease have a very high risk of complications" such as low blood sugar, infections or cardiovascular events, study co-senior author Dr. Ildiko Lingvay noted.

“Yet this population is much less likely to be included in clinical trials or be treated with medications that have proven benefits," said Lingvay, a professor of internal medicine at UT Southwestern.

"Our findings demonstrate that GLP1-RAs can lead to fewer cardiovascular events, less progression of kidney disease, and lower health care costs," she added in a university news release. "These are very impactful outcomes that support the widespread benefits of this class of medications in this high-risk population.”

Zhang agreed, saying it's possible that the data could help change practice.

“Historically, diabetic kidney disease has been difficult to address,” Zhang concluded.

“With further research, we could eventually see new guidelines that include GLP1-RAs as part of a comprehensive treatment approach for diabetes-related kidney disease, potentially improving long-term outcomes and enhancing patient quality of life,” she added.

The findings were published recently in Nature Communications.

Sources

  • UT Southwestern, news release, Feb. 10, 2025

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted February 2025

Read this next

Shedding Pounds in Middle Age Could Add Years to Your Life, Study Finds

WEDNESDAY, May 28, 2025 — Losing just 6.5% of body weight in midlife may lower later risk of disease and premature death, new research shows. Researchers found that people...

Preschool BMI Can Predict Childhood Obesity Risk

WEDNESDAY, May 28, 2025 — Preschoolers who don’t naturally lose weight are more likely to develop full-fledged childhood obesity by age 9, a new study says. Most kids...

Weight-Loss Drugs May Lower Risk Of Obesity-Related Cancers

WEDNESDAY, May 28, 2025 — Popular GLP-1 weight loss drugs like Ozempic and Zepbound can help reduce a woman’s risk for as many as 14 cancers associated with obesity, a...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.